Identification of Pathogenic Mutations in Primary Microcephaly-(MCPH-) Related Three Genes CENPJ, CASK, and MCPH1 in Consanguineous Pakistani Families

Niaz Muhammad Khan,1 Muhammad Shareef Masoud,1 Shahid Mahmood Baig,2,3 Muhammad Qasim,1 and Junlei Chang4

1Department of Bioinformatics and Biotechnology, Government College University Faisalabad, Faisalabad, Pakistan
2Department of Biological and Biomedical Sciences, Agha Khan University Karachi, Pakistan
3Pakistan Science Foundation, 1-Constitution Avenue, G-5/2 Islamabad, Pakistan
4Shenzhen Key Laboratory of Biomimetic Materials and Cellular Immunomodulation, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China

Correspondence should be addressed to Muhammad Qasim; qasemawan@gmail.com and Junlei Chang; jl.chang@siat.ac.cn

Received 2 November 2021; Accepted 20 January 2022; Published 3 March 2022

Microcephaly (MCPH) is a developmental anomaly of the brain known by reduced cerebral cortex and underdeveloped intellectual disability without additional clinical symptoms. It is a genetically and clinically heterogeneous disorder. Twenty-five genes (involved in spindle positioning, Wnt signaling, centriole biogenesis, DNA repair, microtubule dynamics, cell cycle checkpoints, and transcriptional regulation) causing MCPH have been identified so far. Pakistani population has contributed in the identification of many MCPH genes. WES of three large consanguineous families revealed three pathogenic variants of MCPH1, CENPJ, and CASK. One novel (c.1254delT) deletion variant of MCPH1 and one known (c.18delC) deletion variant of CENPJ were identified in family 1 and 2, respectively. In addition to this, we also identified a missense variant (c.1289G>A) of CASK in males individuals in family 3. Missense mutation in the CASK gene is frequent in the boys with intellectual disability and autistic traits which are the common features that are associated with FG Syndrome 4. The study reports novel and reported mutant alleles disrupting the working of genes vital for normal brain functioning. The findings of this study enhance our understanding about the genetic architecture of primary microcephaly in our local pedigrees and add to the allelic heterogeneity of 3 known MCPH genes. The data generated will help to develop specific strategies to reduce the high incidence rate of MCPH in Pakistani population.

1. Introduction

Primary microcephaly is a rare genetically heterogeneous neurodevelopmental condition that specifically affects the cerebral cortex, and the affected individual has a reduced brain weight than the individuals of the same age, ethnicity, and gender [1, 2]. It is characterized by an architecturally normal brain with mild to moderate intellectual disability [3]. Clinically, the severe MCPH is defined as the occipito-frontal head circumference (OFC) of more than 3SD below the mean for gender, age, and ethnicity [4, 5].

It is a recessive hereditary disorder, and most of the MCPH causing mutation occur in genes that are essential for maintaining proper cell cycle and integrity of the cellular genome [6]. Phenotypically and genetically microcephaly is a very heterogeneous disorder with over 900 OMIM phenotype entries and at last count 25 different types of genes with diverse form of linked variants [6, 7]. Majority of these genes express during the proliferation of neural precursor cells (NPCs) in the ventricular zone of the cerebral cortex [8]. The most frequent cause of this clinical disorder is the mutation in WDR62 (WD repeat-containing protein 62) and ASPM
(abnormal spindle-like, microcephaly-associated) genes which together responsible for more than half (½) the cases of MCPH, followed by MCPH1 which is the first and third most common causes of MCPH [9–11]. At cellular level, MCPH1 encode a multifunctional protein that play an important role in chromosome condensation, DNA damage response, cell cycle control, and DNA repair [12]. Many diverse forms of this congenitally rare genetic disorder may involve a compromised division of cortical precursor cells that leads to a reduced proliferation of neurons due to imbalance among symmetric and asymmetric division of the NPCs. Ultimately, the reduced number of neurons leads to the reduced brain volume, as observed in the MCPH patients [13, 14].

Due to the common practice of consanguineous marriages in Pakistani population, the incidence rate of MCPH (though it is a rare recessive disorder) is high (1/10,000) as compared to the European white populations [15]. One reason of high prevalence of microcephaly in Pakistan is the lack of genetic counselling in the country. More than half of marriages in Pakistan are consanguineous that increases the chances of getting autosomal recessive primary microcephaly in the next generation [16]. Thus, proper screening of more population will reduce the incidence rate of MCPH in Pakistani population.

In the current study, WES and Sanger sequencing were used for the identification of genetic components involved in MCPH. Here, we report three variants in MCPH1, CENPJ, and CASK genes segregating with MCPH. The most frequent pathomechanism of mutant alleles in these genes is the dysfunction of MCPH proteins either through excessive apoptosis or dysregulation of cell cycle dynamics impairing mitotic neurogenesis leading to the precipitation of MCPH phenotypes [17, 18]. Findings of the current study will help to better understand the neurogenesis and pathophysiology of MCPH. Furthermore, the variants of MCPH genes reported in this study will help in devising better molecular diagnostic strategies and providing genetic counselling to the affected families.

2. Materials and Methods

2.1. Subjects and Approval of This Research Study. This study was duly approved by the Institutional Review Boards (IRBs) of Government College University Faisalabad-Pakistan and Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, China. Detailed clinical information (videos, photographs, medical records, and interviews), pedigrees, and blood samples were collected after written informed consents from the parents/guardians following the declaration of Helsinki. Patients were physically examined, and their head circumference was measured.

2.2. Whole-Exome Sequencing. DNA specimen from affected subjects of each pedigree were subjected to whole-exome sequencing (WES) using Illumina NovaSeq 6000 platform to recover genomic libraries and sequenced with an average of 100x coverage on an Illumina HiSeq4000 (Illumina, San Diego, CA, USA). Human reference genome sequence (GRCh37) assembly was used as reference, and reads were aligned and mapped to it. GATK version 3.7 was used for variant calling and SnpEff (version 4.2; http://snpeff.sourceforge.net/) was employed for the classification and annotation of variants. Single-nucleotide variants were filtered by using a variant quality score recalibration method. Postannotation filtration of the variants was done by using the public databases like Genome Aggregation Database (gnomAD) and 1,000 Genomes Project. All the variants with minor allele frequency (MAF) > 0.005 were discarded. Among the retained variants (MAF < 0.005), homozygous and compound heterozygous alleles were focused as the most likely transmission mode for these pedigrees was autosomal recessive. No further in silico tools were used for the deletion variants as these result in immature truncation of translation.

2.3. Sanger Sequencing. The predicted identified variants after whole-exome sequencing were validated through genotyping of all available family members and checked which variant is homozygously segregated in all affected individuals with the disease phenotype. Primer3 web resource was used to design a primer for Sanger sequencing (http://bioinfo.ut.ee/primer3-0.4.0/) available in Table 1. Samples were run on Applied Biosystem 3730 Genetic Analyzer using BigDye, respectively. DNASTAR (Lasergene) and Sequencer 5.4.6 (Gene Codes Corporation) were used to analyze the chromatograms.

2.4. In Silico Analysis of the Identified Variants. The pathogenicity of variants was ascertained according to the criteria of the American College of Medical Genetics (ACMG) (Richards et al., [19]). Bioinformatics prediction tools such as SIFT (http://sift-dna.org/sift4g), Polyphen2 Bioinformatics prediction tools such as SIFT (http://sift-dna.org/sift4g), Polyphen2 (http://genetics.bwh.harvard.edu/pph2/), Provean (WEB LINK), Fathmm (http://fathmm.biocompute.org.uk/), and CADD (https://cadd.gs.washington.edu/score) were used to predict the impacts of missense variant on protein foldings. SIFT Indel was used for predicting the effect of deletion mutation on the protein (https://sift.bii.a-star.edu.sg/www/SIFT_indels2.html).

3. Results and Discussion

We report a novel deletion variant in MCPH1 and reported deletion and missense variants in CENPJ and CASK genes, respectively (Figure 1). Gene structures of MCPH1, CENPJ, and CASK genes are shown in Figure 2. All the affected individuals segregated MCPH in recessive inheritance pattern as their parents were normal. Detailed clinical and genetic manifestations in these three families are given in Table 2. In all the affected individuals, MCPH was present as a congenital disorder and with no history of maternal infection or head injury.

Exome sequence analysis of the proband and subsequent Sanger sequencing of all the affected members from 3 unrelated families discovered a homozygous and hemizygous variant in the three different genes, i.e., MCPH1, CENPJ, and CASK.

In an individual (IV-1 and IV-2), from the MC-1, a novel frameshift variant c.1254delT was observed at exon 8 of the MCPH1 gene (Figure 3(a)). The Sanger sequencing demonstrates that single-base deletion c.1254delT in the MCPH1 gene cosegregate with the disease in a homozygous
manner while both parents and normal siblings of the patients were found heterozygous. This frameshift variant causes the damage to asp amino acid at position 419 and loss of function. Interestingly, in silico tool SIFT Indel predicted it pathogenic and cause nonsense-mediated mRNA decay (NMD). The literature survey of this variant showed that the variant has not been reported in the literature or found absent from the large population databases: Human genome mutation database (HGMD), gnomAD, and 1000 Genomes Project and ClinVar.

In the MC-2, three affected female individuals are presented in the fifth generation (IV-3, IV-4, and IV-5). These individuals showed typical microcephaly phenotypes which were in line with the previously reported cases. The exome sequence analysis of three patients revealed previously known homozygous frameshift variant c.18delC at exon 2 of the CENPJ gene [20] (Figure 3(b)). This variant causes change of serine amino acid to proline at position 7 (p. Ser7profs). Subsequent genotyping of the patient’s data through Sanger

Table 1: Primers sequences used to amplify mutation of MCPH1, CENPJ, and CASK.

| ID | Gene | Mutation | Forward | Reverse | Product size |
|----|------|----------|---------|---------|-------------|
| MC-1 | MCPH1 | c.1254delT; p. Asp419fs | ACCAGGAGATCTATCATGCC | AGAAGTCACCGAACTGAAG | 375 |
| MC-2 | CENPJ | c.18delC; p. Ser7fs | GTAGCTCAATGGCCCAATTGC | AGAAATGTCACCGATGCCT | 370 |
| MC-3 | CASK | c.1289G>A; p. Arg430His | CCTGCCATAAAATCCACTC | AGTACAGTCCCTGAAAAGCC | 412 |

![Sanger sequencing chromatograms](image)

**Figure 1:** Sanger sequencing chromatograms of wild-type and mutant sequences showing deletion and substitution mutations in c.1254delT-MCPH1, c.18delC-CENPJ, and c.1289G>A-CASK.

![Schematic representation](image)

**Figure 2:** Schematic representation of exon and intronic regions of human MCPH1, CENPJ, and CASK genes along with the position of known and novel mutations. The white box represents the untranslated regions (UTR). The straight line represents the introns and the rectangle represents the exons. The asterisk sign shows the novel deletion variant in the MCPH1 gene.
Table 2: Clinical and genetic manifestation of microcephaly patients.

| Family individual ID | Gene   | Mutation                      | Affected members | Age on onset (years) | Head circumference (cm) | Intellectual disability | Epilepsy | Hearing loss | Ophthalmological anomalies | Skeletal anomalies | Neurological defect |
|----------------------|--------|-------------------------------|------------------|----------------------|-------------------------|------------------------|----------------|---------------|--------------------------|-------------------|-------------------|
| MC-1                 | MCPH1  | c.1254delT; p. Asp419fs       | 2                |                      |                         |                        |               |              |                          |                   |                   |
| IV-1                 |        |                               | 8                | 44                   | +                       | —                      | +              | —             | —                        | —                 | +                 |
| IV-2                 |        |                               | 15               | 45                   | +                       | —                      | +              | —             | —                        | —                 | +                 |
| MC-2                 | CENPJ  | c.18delC                      | 3                |                      |                         |                        |               |              |                          |                   |                   |
| IV-3                 |        | p. Ser7fs                     | 23               | 37                   | +                       | +                      | +              | —             | —                        | —                 | +                 |
| IV-4                 |        |                               | 17               | 38                   | +                       | +                      | +              | —             | —                        | —                 | +                 |
| IV-5                 |        |                               | 14               | 37                   | +                       | +                      | +              | —             | —                        | —                 | +                 |
| MC-3                 | CASK   | c.1289G>A                     | 2                |                      |                         |                        |               |              |                          |                   |                   |
| IV-2                 |        | p. Arg430His                  | 14               | 37                   | +                       | +                      | +              | —             | —                        | —                 | +                 |
| IV-4                 |        |                               | 10               | 43                   | +                       | +                      | +              | —             | —                        | —                 | +                 |
mutation is present in the highly conserved region of the Fathmm, and MCAP for the resulting protein (Figure 4). This change is predicted highly damaging by SIFT, Polyphen2, arginine at position 430 to Histidine (p. Arg430His). This gene (Figure 3(c)). This mutation causes the change of CASK and phenotype correlations.

Deletion mutation c.1254delT at exon 8 with modiﬁcation in the X-linked intellectual disabilities of varying lethality in IFI144. The present study reports a novel frameshift deletion mutation c.1254delT at exon 8 with modiﬁed amino acid p. Asp419fs (Figure 1). Multiple sequence alignment showed conservation of proline across species. This variant disrupted the structurally and functionally conserved domain of MCPH1 gene resulting in disease phenotype. MCPH1 gene plays a pivotal role in the neurogenesis of the cerebral cortex and regulation of brain size [21, 22]. In situ hybridization revealed an elevated expression of microcephalin in the fetal mouse brain especially near the lateral ventricles during neurogenesis signifying the involvement of MCPH1 gene in the size regulation of the brain cortex [21]. The MCPH1 mouse model revealed abnormal chromosome condensation during mitosis and a decreased skull size [23, 24].

Mutant alleles of MCPH1 gene have been reported with immature chromosome condensation syndrome and primary microcephaly 1. The present study reports a novel frameshift deletion mutation c.1254delT at exon 8 with modiﬁed amino acid p. Asp419fs (Figure 1). Multiple sequence alignment showed conservation of proline across species. This variant disrupted the structurally and functionally conserved domain of MCPH1 gene resulting in disease phenotype. MCPH1 gene plays a pivotal role in the neurogenesis of the cerebral cortex and regulation of brain size [21, 22]. In situ hybridization revealed an elevated expression of microcephalin in the fetal mouse brain especially near the lateral ventricles during neurogenesis signifying the involvement of MCPH1 gene in the size regulation of the brain cortex [21]. The MCPH1 mouse model revealed abnormal chromosome condensation during mitosis and a decreased skull size [23, 24].

The CENPJ (centromere protein j) gene having 17 exons present on chromosome 13q12.2 plays a major part in assembling, rearrangement, and integrity of the microtubules, during the neurogenesis. The structural changes or complete loss of CENPJ gene leads to the damaged centrosome, multiple spindle poles, cell arrest in mitosis, and loss of centrioles. The CENPJ protein is contained to centrosomes in interphase and to the spindle poles during mitosis [25]. Cho et al. found that the exhaustion of CENPJ protein impairs centrosome integrity and mitosis is arrested in cells deﬁcient in CENPJ [26]. The centrosome serves as a microtubule organizing center and is crucial for the regulation of the cell division. Centrosomal mechanism is the key player in regulating brain size [27]. Interaction of CENPJ with other MCPH proteins like WDR62, CEP152, STIL, CEP135, and ASPM results in microtubules binding [12, 28]. Recent studies reveal that CENPJ controls progenitor division and neuronal migration in the brain [29]. Until now, eight mutations are identiﬁed in this gene (including the one reported in this study) and two of them have been reported in Pakistani MCPH families [15]. MC-3 is the 6th serial Pakistani family in which this frameshift variant (c.18delC) is being reported so this CENPJ variant could reasonably be a founder mutation of the Pakistani population.

CASK (OMIM# 300172) is an X-linked gene with 27 exons which encode a protein (calcium/calmodulin-activated serine kinase), with a role in ion channel trafﬁcking, synaptic transmembrane protein anchoring, neural development, and gene expression regulation. CASK gene expression in the mammalian brain is higher than the other organs of the body [30]. Mutations throughout this gene are known to be involved in the X-linked intellectual disabilities of varying lethality in male and female individuals [31]. The clinical symptoms

![Figure 3: MCPH families showing autosomal and X-linked mode of disease segregation. The filled circles and squares show affected females and males. The open circles and squares show the unaffected individuals. Consanguineous marriage is represented by double lines. The (-/-) sign show the recessive homozygous individuals and (-/+). Patient’s facial characteristics represented in photographs reduced head circumference with no other facial dysmorphism. Family MC-3 did not grant consent for their photographs.](image-url)
associated with mutation in the CASK gene is gender specific. In the girls, the severe deletion mutations in the CASK gene is associated with ailment known as mental retardation and microcephaly with pontine and cerebellar hypoplasia (MICPCH) (OMIM#300749), while in male, boy’s epileptic encephalopathies such as Ohtahara syndrome and infantile spasms are most commonly observed [32–34]. Splice site, duplication, nonsense, and deletion mutation in the CASK gene are less frequently observed in the male which may be due to early male lethality [31]. Missense mutation in the CASK gene is frequent in the boys with mental retardation and autistic traits [35]. WES and Sanger sequence analysis revealed previously reported hemizygous missense variant c.1289G>A at exon 14 of the CASK gene (Figure 1) [32]. This mutation causes the change of arginine at position 430 to Histidine (p. Arg430His). This change is predicted highly damaging by SIFT, Polyphen2, Fathmm, and MCAP for the resulting protein. In public databases gnomAD and ClinVar, this mutation is present with conflicting interpretation and uncertain clinical significance. Segregation analysis of the variant in the normal mother and sibling found heterozygous which is suggesting recessive carrier for this mutation. Females with missense heterozygous mutations may have very mild cognitive deficits with no microcephaly or cerebellar hypoplasia, suggesting an X-linked recessive inheritance pattern [35]. This variant is present in the highly conserved region of the CASK protein. Based upon the American College of Medical Genetics and Genomics guideline for variant clinical interpretation, we can confidently say that the variant c.1289G>A (p. Arg430His) is responsible for the phenotype of the patients presented in this study [36].

4. Conclusion

The current study reports one novel and two previously reported mutations in three Pakistani MCPH families in well-studied MCPH genes. Functional assessment of the novel mutation will clarify its impact on neurogenesis and the development of microcephaly. The findings of this study expand the mutation dataset related to MCPH in the Pakistani population and pave the way for better genotype-phenotype correlations and better understanding and management of MCPH.

Data Availability

All the relevant data are included in the manuscript.

Ethical Approval

This study was approved by the ethical committee of Government College University, Faisalabad, Pakistan, and Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences.

Consent

All participants or their guardians provided written informed consent for this study. Informed written consent for publication of medical data and images was also obtained from all participants and the legal guardian of affected subjects.

Conflicts of Interest

The authors declare that they have no conflict of interests.

Authors’ Contributions

Niaz Muhammad Khan did the investigation, methodology, and writing-original draft. Muhammad Shareef Masoud did the software acquisition and review and editing. Shahid Mahmood Baig did the supervision. Muhammad Qasim did the conceptualization, investigation, resource acquisition, and validation. Junle Chang did the conceptualization, funding acquisition, investigation, resource acquisition, and validation.

Acknowledgments

The authors thank all the participating patients and the families for their cooperation to conduct this study. The work was supported by the National Natural Science Foundation of China (81771293 to JC), Science Technology and Innovation Commission of Shenzhen Municipality (ZDSYS20190902093409851, SGLH20180625142404672, JCYJ20210324115800003), International collaboration project of Chinese Academy of Sciences (172644KYSB202000045), and Guangdong Innovation Platform of Translational Research for Cerebrovascular Diseases. B. H. is supported by Chinese Government Scholarship (CGS) for International Students.

References

[1] A. Fujimori, K. Itoh, S. Goto et al., “Disruption of _Aspm_ causes microcephaly with abnormal neuronal differentiation,” *Brain and Development*, vol. 36, no. 8, pp. 661–669, 2014.
mary microcephaly can tell us about brain growth, and CEP135 underlying autosomal recessive primary microcephaly, vol. 3, no. 12, pp. 369–385, 2017.

[5] H. Wang, “Modeling neurological diseases with Human brain organoids,” Frontiers in Synaptic Neuroscience, vol. 10, pp. 1–14, 2018.

[6] S. Kovvali, D. S. Bhargav, N. Sreedevi, N. Swapna, and S. Vivek, “Whole exome sequencing identifies a novel homozygous frameshift mutation in the ASPM gene, which causes microcephaly 5, primary, autosomal recessive,” F1000Research, vol. 6, pp. 1–8, 2017.

[7] M. von der Hagen, M. Pivarcsi, J. Liebe et al., “Whole-exome sequencing is a powerful approach for establishing the etiological diagnosis in patients with intellectual disability and microcephaly,” BMC Medical Genomics, vol. 9, no. 1, pp. 1–9, 2016.

[8] J. Zhou, Y. Zhi, J. Yu, and D. Xu, “The yin and yang of autosomal recessive primary microcephaly genes: insights from neurogenesis and carcinogenesis,” International Journal of Molecular Sciences, vol. 21, no. 5, 2020.

[9] P. Rump, O. Jazayeri, K. van Dijk-Bos et al., “Whole-exome sequencing is a powerful approach for establishing the etiological diagnosis in patients with intellectual disability and microcephaly,” BMC Medical Genomics, vol. 9, no. 1, pp. 1–9, 2016.

[10] J. Chen, N. Ingham, S. Clare et al., “CDK5RAP2 and CENPJ controls brain size, Neurogenetics,” vol. 13, 2019.

[11] X. Zhou, Y. Zhi, J. Yu, and D. Xu, “The yin and yang of autosomal recessive primary microcephaly genes: insights from neurogenesis and carcinogenesis,” International Journal of Molecular Sciences, vol. 21, no. 5, 2020.

[12] X. Zhou, Y. Zhi, J. Yu, and D. Xu, “The yin and yang of autosomal recessive primary microcephaly genes: insights from neurogenesis and carcinogenesis,” International Journal of Molecular Sciences, vol. 21, no. 5, 2020.

[13] M. Barbelanne and W. Y. Tsang, “Molecular and cellular basis of autosomal recessive primary microcephaly,” BioMed Research International, vol. 2014, 13 pages, 2014.

[14] E. C. Gilmore and C. A. Walsh, “GENETICS CAUSING MICROCEPHALY: A WINDOW INTO BRAIN DEVELOPMENT AND EVOLUTION,” Frontiers in Cellular Neurobiology, vol. 9, pp. 1–14, 2015.

[15] M. Barbelanne and W. Y. Tsang, “Molecular and cellular basis of autosomal recessive primary microcephaly,” BioMed Research International, vol. 2014, 13 pages, 2014.

[16] E. C. Gilmore and C. A. Walsh, “GENETICS CAUSING MICROCEPHALY: A WINDOW INTO BRAIN DEVELOPMENT AND EVOLUTION,” Frontiers in Cellular Neurobiology, vol. 9, pp. 1–14, 2015.

[17] M. I. Naseer, M. Rasool, S. Sagoty et al., “A novel WDR62 mutation causes primary microcephaly in a large consanguineous Saudi family,” Annals of Saudi Medicine, vol. 37, no. 2, pp. 148–153, 2017.

[18] J. Cox, A. P. Jackson, J. Bond, and C. G. Woods, “What primary microcephaly can tell us about brain growth,” Trends in Molecular Medicine, vol. 12, no. 8, pp. 358–366, 2006.

[19] S. Zaqout, D. Morris-Rosendahl, and A. M. Kaindl, “Autosomal recessive primary microcephaly (MCPH): an update,” Neuropediatrics, vol. 48, no. 3, pp. 135–142, 2017.

[20] S. Richards, N. Aziz, S. Bale et al., “Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology,” Genetics in medicine, vol. 17, no. 5, pp. 405–423, 2015.

[21] I. Ahmad, S. M. Baig, A. R. Abdulkareem et al., “Genetic heterogeneity in Pakistani microcephaly families revisited,” Clinical Genetics, vol. 92, no. 1, pp. 62–68, 2017.

[22] A. P. Jackson, H. Eastwood, S. M. Bell et al., “Identification of microcephalin, a protein implicated in determining the size of the human brain,” The American Journal of Human Genetics, vol. 71, no. 1, pp. 136–142, 2002.

[23] X. Xu, J. Lee, and D. F. Stern, “Microcephalin is a DNA damage response protein involved in regulation of _CHK1_ and _BRCA1_,” Journal of Biological Chemistry, vol. 279, no. 33, pp. 34091–34094, 2004.

[24] J. Chen, N. Ingham, S. Clare et al., “Mcp1-deficient mice reveal a role for MCP1H in otitis media,” PLoS one, vol. 8, no. 3, article e58156, 2013.

[25] M. Trimborn, M. Ghani, D. J. Walther et al., “Establishment of a mouse model with misregulated chromosome condensation due to defective Mcph1 function,” PLoS ONE, vol. 5, no. 2, 2010.

[26] M. Naveed, S. K. Kazmi, M. Amin et al., “Comprehensive review on the molecular genetics of autosomal recessive primary microcephaly (MCPH),” Genetics Research, vol. 100, p. e7, 2018.

[27] J. H. Cho, C. I. Chang, C. Y. Chen, and T. K. Tang, “Depletion of CPAP by RNAi disrupts centrosome integrity and induces multipolar spindles,” Biochemical and Biophysical Research Communications, vol. 339, no. 3, pp. 742–747, 2006.

[28] J. Bond, E. Roberts, K. Springell et al., “A centrosomal mechanism involving CDK5RAP2 and CENP1 controls brain size,” Nature Genetics, vol. 37, no. 4, pp. 353–355, 2005.

[29] D. Jayaraman, A. Kodani, D. M. Gonzalez et al., “Microcephaly proteins Wdr62 and Aspm define a mother centriole complex regulating centriole biogenesis, apical complex, and cell fate,” Neuron, vol. 92, no. 4, pp. 813–828, 2016.

[30] P. P. Garcez, J. Diaz-Alonso, I. Crespo-Enriquez, D. Castro, D. Bell, and F. Guillenot, “CENP1/CPAP regulates progenitor divisions and neuronal migration in the cerebral cortex downstream of Ascl1,” Nature Communications, vol. 6, 2015.

[31] Y.-P. Hsu, “The role of the MAGUK protein CASK in neural development and synaptic function,” Current Medicinal Chemistry, vol. 13, no. 16, pp. 1915–1927, 2006.

[32] L. C. LE, V. Chavan, A. F. Elias et al., “Two microcephaly-associated novel missense mutations in CASK specifically disrupt the CASK–neurexin interaction,” Human genetics, vol. 137, no. 3, pp. 231–246, 2019.

[33] D. Jayaraman, A. Kodani, D. M. Gonzalez et al., “Microcephaly proteins Wdr62 and Aspm define a mother centriole complex regulating centriole biogenesis, apical complex, and cell fate,” Neuron, vol. 92, no. 4, pp. 813–828, 2016.

[34] J. Bond, E. Roberts, K. Springell et al., “A centrosomal mechanism involving CDK5RAP2 and CENP1 controls brain size,” Nature Genetics, vol. 37, no. 4, pp. 353–355, 2005.

[35] D. Jayaraman, A. Kodani, D. M. Gonzalez et al., “Microcephaly proteins Wdr62 and Aspm define a mother centriole complex regulating centriole biogenesis, apical complex, and cell fate,” Neuron, vol. 92, no. 4, pp. 813–828, 2016.

[36] P. P. Garcez, J. Diaz-Alonso, I. Crespo-Enriquez, D. Castro, D. Bell, and F. Guillenot, “CENP1/CPAP regulates progenitor divisions and neuronal migration in the cerebral cortex downstream of Ascl1,” Nature Communications, vol. 6, 2015.

[37] Y.-P. Hsu, “The role of the MAGUK protein CASK in neural development and synaptic function,” Current Medicinal Chemistry, vol. 13, no. 16, pp. 1915–1927, 2006.

[38] L. C. LE, V. Chavan, A. F. Elias et al., “Two microcephaly-associated novel missense mutations in CASK specifically disrupt the CASK–neurexin interaction,” Human genetics, vol. 137, no. 3, pp. 231–246, 2019.

[39] U. Moog, T. Bierhals, K. Brand et al., “Phenotypic and molecular insights into CASK-related disorders in males,” Orphanet Journal of Rare Diseases, vol. 10, no. 1, 2015.

[40] S. Richards, N. Aziz, S. Bale et al., “Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology,” Genetics in medicine, vol. 17, no. 5, pp. 405–423, 2015.
transcriptional changes in synaptic and cellular metabolic pathways,” *Experimental Neurology*, vol. 329, article 113319, 2020.

[35] A. Hackett, P. S. Tarpey, A. Licata et al., “CASK mutations are frequent in males and cause X-linked nystagmus and variable XLMR phenotypes,” *European Journal of Human Genetics*, vol. 18, no. 5, pp. 544–552, 2010.

[36] J. Wang and Y. Shen, “When a ‘disease-causing mutation’ is not a pathogenic variant,” *Clinical chemistry*, vol. 713, pp. 711–713, 2014.